| DCAPI1510 |
Ixabepilone
Featured
|
Ixabepilone (Azaepothilone B; BMS 247550) is an epothilone B analog and nontaxane microtubule-stabilizing compound with clinical activity in a range of solid tumors. |
|
| DC9272 |
K 858
Featured
|
K 858 is an ATP-uncompetitive mitotic kinesin Eg5 inhibitor, which does not effect microtubule dynamics. |
|
| DC12220 |
Kinesore |
Kinesore is an inhibitor of the KLC2-SKIP Interaction. |
|
| DC11524 |
Mavacamten（MYK-461）
Featured
|
Mavacamten（MYK-461）is a small molecule that reduces contractility by decreasing the ATPase activity of the cardiac myosin heavy chain. |
|
| DC10711 |
ML-327
Featured
|
ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT). |
|
| DC2082 |
Monastrol
Featured
|
Monastrol is a reversible, cell-permeable inhibitor of the motor protein Eg5 (kinesin family protein 11, Kif11), blocking basal ATPase activity in vitro (IC50 = 6.1 µM) and inducing the formation of monoastral spindles in cell-based assays (IC50 = 51.3 μM |
|
| DC11241 |
MP-HJ-1b |
MP-HJ-1b is a novel potent inhibitor of microtubule and tumor cell growth, binds the colchicine pocket at the intra-dimer interface, depolymerizes microtubules and affects spindle formation. |
|
| DC8715 |
NSC305787 |
NSC305787 is a small molecule inhibitor of PKC, with IC50 of 8.3 μM, 9.4 μM, 55 μM for PKCΙ phosphorylation of recombinant ezrin, of moesin, and of radixin. |
|
| DC7023 |
Ombrabulin
Featured
|
Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors. |
|
| DC10981 |
Plocabulin |
Plocabulin (PM060184) is a novel tubulin-binding agent binding to αβ-tubulin dimer with nanomolar affinity, inhibits a panel of 23 tumor cell lines with GI50 of 20 pM-5 nM. |
|
| DC8224 |
Lifitegrast(SAR 1118)
Featured
|
SAR 1118 is a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist for treating dry eye. |
|
| DC5137 |
SB 743921
Featured
|
SB743921 is a kinesin spindle protein (KSP) inhibitor with Ki of 0.1 nM, almost no affinity to MKLP1, Kin2, Kif1A, Kif15, KHC, Kif4 and CENP-E. |
|
| DC10390 |
TD139
Featured
|
TD139 is a novel high-affinity inhibitor of the galectin-3 carbohydrate binding domain with a Kd of 14 nM. |
|
| DC9489 |
Tirofiban (hydrochloride monohydrate)
Featured
|
Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist
|
|
| DC7327 |
Tirofiban(L700462;MK383)
Featured
|
Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist. |
|
| DC7777 |
Valategrast (R411) |
Valategrast (R411), a small molecule antagonist of α4β1 integrin, represents a potential therapy for asthma |
|
| DC11225 |
sabizabulin(VERU-111)
Featured
|
VERU-111 (Sabizabulin) is a novel potent colchicine binding site inhibitor (CBSI) in tubulin with potential anticancer activities. Sabizabulin is a novel oral agent with both anti-viral and anti-inflammatory activities.Sabizabulin is a cytoskeleton disruptor which by causing microtubule depolymerization has both anti-viral and anti-inflammatory activity and could be effective against the SARS-CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to be transported, replicated, assembled, and released from the cell. In addition, microtubule depolymerization drugs that target the “colchicine binding site” of microtubules, like sabizabulin, also have strong anti-inflammatory effects, including the potential to treat the cytokine release syndrome (cytokine storm) and septic shock induced by the SARS-CoV-2 viral infection that is associated with high COVID-19 mortality rates. |
|
| DC11227 |
VERU-111 analogue 13f |
VERU-111 analogue 13f is a novel potent colchicine binding site inhibitor (CBSI) in tubulin with potential anticancer activities. |
|
| DC4184 |
Vinorelbine Ditartrate
Featured
|
Vinorelbine (Navelbine) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM. |
|
| DC9490 |
Zaurategrast |
Zaurategrast(CDP-323) is an oral α4-integrin inhibitor.
|
|
| DC10034 |
GLPG0187
Featured
|
GLPG0187 is a small molecule integrin receptor antagonist (IRA) with potential antineoplastic activity. |
|
| DC28075 |
αvβ1 integrin-IN-1 |
αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects. |
|
| DC28106 |
ML-9 Free Base |
ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation. |
|
| DC28176 |
BMS-688521 |
BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model. |
|
| DC28280 |
c(phg-isoDGR-(NMe)k) TFA |
c(phg-isoDGR-(NMe)k) TFA is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM. |
|
| DC28890 |
Batabulin |
Batabulin (T138067) is an antitumor agent, which binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin affects cell morphology and leads to cell-cycle arrest ultimately induce apoptotic cell death. Batabulin has efficacy against multidrug-resistant (MDR) tumors. |
|
| DC28956 |
Valecobulin hydrochloride |
Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine prodrug of S516 and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.
|
|
| DC29103 |
Gap19
Featured
|
Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial. |
|
| DC29104 |
Gap19 TFA |
Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial. |
|
| DC29131 |
α2β1 Integrin Ligand Peptide (TFA) |
α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors. |
|
